Home > Press > Elsevier Business Intelligence's 'IN3 Medical Device 360° London' Conference to Feature Exceptional Line-Up of International Device Investors, April 25-26, 2012
Abstract:
Elsevier Business Intelligence, the medtech industry's leading provider of strategic partnership and investment conferences, announces an outstanding roster of presenting senior global investors for its 'IN3 Medical Device 360° London' medical technology investment and partnering conference, being held April 25-26, 2012, at the Millennium Gloucester Hotel & Conference Centre, London Kensington.
'IN3 Medical Device 360° London' will feature presentations by approximately two dozen early-, mid- and late-stage start-up companies from around the world seeking funding and/or strategic partnership, developing innovative new technologies in the areas of cardiovascular biomaterials, cartilage repair, cancer staging, nanotechnology, neurostimulation, infection control, diagnostics, laparoscopic surgery and much more. Presenting companies to date include: AiMedics, Anethon, CellCoTec, Endomagnetics, Enox BioPharma, Implandata Ophthalmic Products, N8 Medical, NUUBO, QSTREAM VASCULAR, Replication Medical, Sapiens Steering Brain Stimulation, SeamVad, Sensible Medical Innovations, Soft Tissue Regeneration, Specialty Scanners, Vantix, and Vascular Flow Technologies.
The conference also will feature an outstanding agenda of panels and networking sessions with industry thought leaders discussing pressing issues facing the global device industry in 2012 and beyond. Participating speakers include: Edward Andrle, VP, Business Development & Strategy, Sorin Group; Arnaud Bernaert, SVP, Corporate Mergers and Acquisitions, Philips Healthcare; Aris Constantinides, Investment Director, NBGI Ventures; Bulend Corbacioglu, VP, Business Development and Licensing, Covidien; Townsend Goddard, Director, Business Development & Strategic Planning, Stryker; Victor Higgs, Managing Director, Applied Nanodetectors; Alan O'Connell, Partner, Seroba Kernel Life Sciences; Antoine Papiernik, Managing Partner, Sofinnova Partners; Stan Rabinovich, VP, Advanced Technology, Edwards LifeSciences; Thom Rasche, Partner, Earlybird Venture Capital; and Bleddyn Rees, Head of Healthcare, Wragge & Co. LLP, and Director, ECHAlliance.
Panel topics will include: Corporate Buy-Side Perspective: What Are Buyers Looking for in 2012?; Business Challenges Facing Wireless Health Ventures; and Raising Venture Capital in Europe: The Best of Times or the Worst of Times? In addition, the two-day program will feature profile presentations by the following healthcare investment firms, among others: Forbion, Gilde Healthcare Partners, Fountain Healthcare Partners, Wellington Partners, Delta Partners, Peppermint VIP, and Family Office Fund. Partnering software will be available to all registered attendees prior to the conference so that one-on-one onsite meetings can be pre-arranged.
This two-day special event will benefit a wide variety of participants in the global medical device sector: start-ups seeking investment or strategic partnerships, investment firms, VCs, mid-size and large medical device manufacturers, and service providers. Emerging medtech companies that would like to apply to present in London should contact Kayleen Kell at 949-797-7142, or email .
IN3 Medical Device 360° London will be held at the Millennium Gloucester Hotel & Conference Centre, London Kensington. Event co-sponsors to date include Ronald Trahan Associates Inc., Aptiv Solutions, Marketwire, Mass Medical Angels, Life Science Intelligence and Scisive Consulting LP. Visit www.IN3London.com for full conference and registration details. EBI will be hosting two additional IN3 Medical Device 360° events in 2012, in Boston and San Francisco; visit www.elsevierbi.com/conferences for more information.
####
About Elsevier Business Intelligence
Elsevier Business Intelligence (EBI), an Elsevier company built on the heritage of F-D-C Reports, Windhover Information and Medtech Insight, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, EBI places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. EBI (www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.
For more information, please click here
Contacts:
Kayleen Kell
949-797-7142
Ronald Trahan, APR
Ronald Trahan Associates Inc.
508-359-4005, x108
Copyright © Marketwire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||